139 related articles for article (PubMed ID: 1245160)
21. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
[TBL] [Abstract][Full Text] [Related]
22. [Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
Klemens UH; von Löwis P
Dtsch Med Wochenschr; 1973 Jun; 98(24):1197-202. PubMed ID: 4350685
[No Abstract] [Full Text] [Related]
23. [Combination of clofibrate and phenformin in the treatment of endogenous hypertriglyceridaemia (author's transl)].
Vogelberg KH
Dtsch Med Wochenschr; 1976 Dec; 101(51):1868-71. PubMed ID: 1001205
[TBL] [Abstract][Full Text] [Related]
24. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Nye ER; Sutherland WH; Temple Wa
N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
[TBL] [Abstract][Full Text] [Related]
25. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
Jung W; Kremer GJ; Müller D
MMW Munch Med Wochenschr; 1975 Oct; 117(44):1783-6. PubMed ID: 171564
[TBL] [Abstract][Full Text] [Related]
26. Influence of nicotinic acid, niceritrol and beta-pyridylcarbinol on experimental hyperlipidemia and atherosclerosis in mini-pigs.
Lundholm L; Jacobsson L; Brattsand R; Magnusson O
Atherosclerosis; 1978 Feb; 29(2):217-39. PubMed ID: 646851
[No Abstract] [Full Text] [Related]
27. [Long-term effect of alufibrate in various types of hyperlipidaemia (author's transl)].
Stähelin HB; Hartmann G
Dtsch Med Wochenschr; 1974 Jun; 99(26):1392-4 passim. PubMed ID: 4601124
[No Abstract] [Full Text] [Related]
28. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
Krut LH; Seftel HC; Joffe BI
S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
[TBL] [Abstract][Full Text] [Related]
29. The treatment of hypercholesterolemia with beta-pyridylcarbinol. Part 5. Report on 16 cases with severe hypercholesterolemia treated for 12 years.
Zöllner N; Keller CH; Wolfram G
Atherosclerosis; 1977 Apr; 26(4):611-5. PubMed ID: 856228
[TBL] [Abstract][Full Text] [Related]
30. [Dose-effects studies with bezafibrate in patients with hypercholesterolemia and hypertriglyceridemia (author's transl)].
Adam O; Wolfram G; Lang PD; Zöllner N
MMW Munch Med Wochenschr; 1979 Mar; 121(9):319-22. PubMed ID: 106264
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of primary hyperlipoproteinaemia types, IIa, IIb, 3 and IV with clofibrate (author's transl)].
von Löwis P; Klemens UH
Dtsch Med Wochenschr; 1973 Dec; 98(49):2328-33. PubMed ID: 4357927
[No Abstract] [Full Text] [Related]
32. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(12):1682-4. PubMed ID: 6686774
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
Sterner W; Chibanguza G; Metz G
Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
[TBL] [Abstract][Full Text] [Related]
34. [Beta-pyridyl-carbinol in the treatment of hyperlipoproteinemia].
Kleiber G; Leickert KH
ZFA (Stuttgart); 1979 Jul; 55(21):1199-205. PubMed ID: 157647
[No Abstract] [Full Text] [Related]
35. [Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B (author's transl)].
Mertz DP; Suermann I; Göhmann E
MMW Munch Med Wochenschr; 1978 Aug; 120(34):1097-9. PubMed ID: 210375
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
Vecchio TJ; Linden CV; O'Connell MJ; Heilman J
Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415
[TBL] [Abstract][Full Text] [Related]
37. Effect of calcium p-chlorphenoxyisobutyrate and calcium carbonate on plasma lipids and lipoproteins of patients with hyperlipoproteinaemia.
Koskinen P; Inkovaara J; Ala-Kaila K; Salo M; Nikkari T
Ann Clin Res; 1977 Dec; 9(6):335-41. PubMed ID: 356720
[TBL] [Abstract][Full Text] [Related]
38. [Clinical and therapeutic evaluation of a new antilipemic substance].
de Aguiar Magano L
Arch Sci Med (Torino); 1980; 137(1):131-9. PubMed ID: 7458646
[TBL] [Abstract][Full Text] [Related]
39. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
Wechsler JG; Hutt V; Klör HU; Ditschuneit H
Artery; 1980; 8(6):519-29. PubMed ID: 7259531
[TBL] [Abstract][Full Text] [Related]
40. Gemfibrozil and clofibrate in the treatment of hyperlipidaemias. A comparative trial.
Eisalo A; Manninen V
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):44-6. PubMed ID: 798196
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
